Braveheart Bio to present 52-week BHB-1893 data at AHA Scientific Sessions

BRVE•2026-10-30

Braveheart Bio will present 52-week extension results on BHB-1893’s efficacy and safety in obstructive hypertrophic cardiomyopathy at the American Heart Association Scientific Sessions in Chicago, Nov. 6-9, 2026.

1. Presentations set for Nov. 6

Braveheart Bio will make two presentations on Nov. 6. One will cover 52-week extension results for BHB-1893 in obstructive hypertrophic cardiomyopathy; the other will address the drug’s effects on diastolic function in non-obstructive hypertrophic cardiomyopathy.

Braveheart Bio to present 52-week BHB-1893 data at AHA Scientific Sessions

1. Presentations set for Nov. 6

Related News

Coherent Corp.: B. Riley cuts target price to $262 from $297

Maplebear Inc.: Morgan Stanley raises target price to $65 from $58

Symbotic climbs after expanded automation deal with Walmart

Service Corporation International: Oppenheimer cuts target price to $88 from $97

India bonds buckle for fourth straight month on oil's climb